Literature DB >> 8155016

Facioscapulohumeral muscular dystrophy in early childhood.

O F Brouwer1, G W Padberg, C Wijmenga, R R Frants.   

Abstract

OBJECTIVE: To determine the occurrence and the clinical and genetic variability of early-onset facioscapulohumeral muscular dystrophy (FSHD).
DESIGN: Patients were derived from a large series of patients who participated in a genetic study of FSHD in the Netherlands. PATIENTS: A group of 96 patients of 17 families with autosomal dominant FSHD, nine sporadic cases of FSHD, and 35 children at risk for having the FSHD gene was searched for the presence of early-onset cases. Criteria for early-onset FSHD were (1) signs or symptoms of facial weakness before the age of 5 years and (2) signs or symptoms of shoulder girdle weakness before the age of 10 years.
RESULTS: Six early-onset cases (four familial, two sporadic) were identified. Four of five cases showed an abnormal DNA fragment with the probe p13E-11, which has been shown to detect DNA rearrangements in FSHD patients. The clinical symptoms in these early-onset cases showed great variability with respect to rate of progression of muscle weakness, the association of hearing loss and retinopathy, and the expression of the disorder in parents and siblings.
CONCLUSIONS: Infantile FSHD has been suggested to be a separate form of the disease, often accompanied by sensorineural hearing loss and retinal telangiectasia. Our findings, as well as the fact that both hearing loss and retinal vasculopathy have been recently shown to be part of FSHD, suggest that early-onset FSHD is not a separate entity, but part of a wide clinical spectrum of FSHD.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8155016     DOI: 10.1001/archneur.1994.00540160085011

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  26 in total

1.  Orthognathic surgery in a case of infantile facioscapulohumeral muscular dystrophy with macroglossia.

Authors:  Marcus Stephan Kriwalsky; Marcus Deschauer; Alexander Walter Eckert; Johannes Schubert; Stephan Zierz
Journal:  Oral Maxillofac Surg       Date:  2008-12

2.  Isolated facial diplegia and very late-onset myopathy in two siblings: atypical presentations of facioscapulohumeral dystrophy.

Authors:  Juan J Figueroa; John E Chapin
Journal:  J Neurol       Date:  2009-10-14       Impact factor: 4.849

3.  Early onset as a marker for disease severity in facioscapulohumeral muscular dystrophy.

Authors:  Rianne J M Goselink; Karlien Mul; Caroline R van Kernebeek; Richard J L F Lemmers; Silvère M van der Maarel; Tim H A Schreuder; Corrie E Erasmus; George W Padberg; Jeffrey M Statland; Nicol C Voermans; Baziel G M van Engelen
Journal:  Neurology       Date:  2018-12-19       Impact factor: 9.910

Review 4.  Facioscapulohumeral muscular dystrophy as a model for epigenetic regulation and disease.

Authors:  Charis L Himeda; Takako I Jones; Peter L Jones
Journal:  Antioxid Redox Signal       Date:  2014-12-04       Impact factor: 8.401

5.  Medication adherence in patients with myotonic dystrophy and facioscapulohumeral muscular dystrophy.

Authors:  Bryan P Fitzgerald; Kelly M Conn; Joanne Smith; Andrew Walker; Amy L Parkhill; James E Hilbert; Elizabeth A Luebbe; Richard T Moxley
Journal:  J Neurol       Date:  2016-10-12       Impact factor: 4.849

6.  If you build a rare disease registry, will they enroll and will they use it? Methods and data from the National Registry of Myotonic Dystrophy (DM) and Facioscapulohumeral Muscular Dystrophy (FSHD).

Authors:  James E Hilbert; John T Kissel; Elizabeth A Luebbe; William B Martens; Michael P McDermott; Donald B Sanders; Rabi Tawil; Charles A Thornton; Richard T Moxley
Journal:  Contemp Clin Trials       Date:  2011-11-26       Impact factor: 2.226

Review 7.  Genotype-phenotype correlations in FSHD.

Authors:  Nikolay Zernov; Mikhail Skoblov
Journal:  BMC Med Genomics       Date:  2019-03-13       Impact factor: 3.063

8.  A multinational study on motor function in early-onset FSHD.

Authors:  Jean K Mah; Jia Feng; Marni B Jacobs; Tina Duong; Kate Carroll; Katy de Valle; Cara L Carty; Lauren P Morgenroth; Michela Guglieri; Monique M Ryan; Paula R Clemens; Mathula Thangarajh; Richard Webster; Edward Smith; Anne M Connolly; Craig M McDonald; Peter Karachunski; Mar Tulinius; Amy Harper; Avital Cnaan; Yi-Wen Chen
Journal:  Neurology       Date:  2018-03-14       Impact factor: 9.910

9.  DUX4 Transcript Knockdown with Antisense 2'-O-Methoxyethyl Gapmers for the Treatment of Facioscapulohumeral Muscular Dystrophy.

Authors:  Kenji Rowel Q Lim; Adam Bittel; Rika Maruyama; Yusuke Echigoya; Quynh Nguyen; Yiqing Huang; Kasia Dzierlega; Aiping Zhang; Yi-Wen Chen; Toshifumi Yokota
Journal:  Mol Ther       Date:  2020-10-15       Impact factor: 11.454

10.  Cardiac Involvement in Facioscapulohumeral Muscular Dystrophy (FSHD).

Authors:  Allison Ducharme-Smith; Stefan Nicolau; C Anwar A Chahal; Kirstie Ducharme-Smith; Shujah Rehman; Keerthi Jaliparthy; Nadeem Khan; Christopher G Scott; Erik K St Louis; Teerin Liewluck; Virend K Somers; Grace Lin; Peter A Brady; Margherita Milone
Journal:  Front Neurol       Date:  2021-05-24       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.